Published in J Med Chem on July 14, 2005
Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors. Biochem Biophys Res Commun (2013) 0.89
Come-back of phenanthridine and phenanthridinium derivatives in the 21st century. Beilstein J Org Chem (2014) 0.86
Expanding the palette of phenanthridinium cations. Chemistry (2014) 0.75
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Integrated 3D-printed reactionware for chemical synthesis and analysis. Nat Chem (2012) 3.23
Epigenome-wide association study in the European Prospective Investigation into Cancer and Nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Mol Genet (2012) 3.07
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Comparison of plethysmographic and helium dilution lung volumes: which is best for COPD? Chest (2009) 2.98
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Case scenario: acute postoperative negative pressure pulmonary edema. Anesthesiology (2010) 2.54
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol (2007) 2.48
Health risk of chrysotile revisited. Crit Rev Toxicol (2013) 2.45
DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst (2005) 2.43
Configurable 3D-Printed millifluidic and microfluidic 'lab on a chip' reactionware devices. Lab Chip (2012) 2.17
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res (2007) 2.08
Group B streptococcus infection: risk and prevention. Pract Midwife (2013) 1.99
Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol Ther (2011) 1.96
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant (2005) 1.90
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Thrombocytopenia associated with chronic liver disease. J Hepatol (2008) 1.89
Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 1.88
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci U S A (2010) 1.83
Polyoxometalate clusters, nanostructures and materials: from self assembly to designer materials and devices. Chem Soc Rev (2006) 1.79
Signalling cell cycle arrest and cell death through the MMR System. Carcinogenesis (2005) 1.77
CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett (2008) 1.75
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther (2011) 1.70
Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol (2008) 1.66
The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res (2004) 1.65
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res (2006) 1.53
Intragenic ATM methylation in peripheral blood DNA as a biomarker of breast cancer risk. Cancer Res (2012) 1.52
Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res (2011) 1.47
Liver transplantation outcomes among Caucasians, Asian Americans, and African Americans with hepatitis B. Liver Transpl (2009) 1.46
Progressive granulomatous pneumonitis in response to cosmetic subcutaneous silicone injections in a patient with HIV-1 infection: case report and review of the literature. Arch Pathol Lab Med (2012) 1.46
New approaches to the analysis of high connectivity materials: design frameworks based upon 4(4)- and 6(3)-subnet tectons. Acc Chem Res (2005) 1.45
Polyoxometalates: building blocks for functional nanoscale systems. Angew Chem Int Ed Engl (2010) 1.44
Face-directed self-assembly of an electronically active Archimedean polyoxometalate architecture. Nat Chem (2010) 1.43
The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol (2004) 1.41
Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol (2013) 1.38
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Recommendations for improved acute pain services: Canadian collaborative acute pain initiative. Pain Res Manag (2004) 1.33
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res (2008) 1.33
Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat (2004) 1.32
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res (2011) 1.28
Improved validation of peptide MS/MS assignments using spectral intensity prediction. Mol Cell Proteomics (2006) 1.28
DNA methylation as a long-term biomarker of exposure to tobacco smoke. Epidemiology (2013) 1.28
Identification of novel high-frequency DNA methylation changes in breast cancer. PLoS One (2007) 1.22
Spirometry testing standards in spinal cord injury. Chest (2003) 1.22
Antigenic diversity is generated by distinct evolutionary mechanisms in African trypanosome species. Proc Natl Acad Sci U S A (2012) 1.22
Decoupling hydrogen and oxygen evolution during electrolytic water splitting using an electron-coupled-proton buffer. Nat Chem (2013) 1.21
Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res (2005) 1.20
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17
Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival. Clin Cancer Res (2011) 1.15
The promises and pitfalls of epigenetic therapies in solid tumours. Eur J Cancer (2009) 1.15
The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res (2004) 1.15
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Genome screen to detect linkage to intracranial aneurysm susceptibility genes: the Familial Intracranial Aneurysm (FIA) study. Stroke (2008) 1.10
3D printed high-throughput hydrothermal reactionware for discovery, optimization, and scale-up. Angew Chem Int Ed Engl (2014) 1.10
Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury. Arch Phys Med Rehabil (2006) 1.09
Critical evaluation of p53 as a prognostic marker in ovarian cancer. Expert Rev Mol Med (2004) 1.08
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
Modular redox-active inorganic chemical cells: iCHELLs. Angew Chem Int Ed Engl (2011) 1.07
Microcalorimetric study of ammonia chemisorption on H3PW12O40 supported onto mesoporous synthetic carbons and SBA-15. Langmuir (2006) 1.05
Clinical ventilator adjustments that improve speech. Chest (2003) 1.04
Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol (2005) 1.04
Observation of Fe(V)=O using variable-temperature mass spectrometry and its enzyme-like C-H and C=C oxidation reactions. Nat Chem (2011) 1.04
Growth of Rhodospirillum rubrum on synthesis gas: conversion of CO to H2 and poly-beta-hydroxyalkanoate. Biotechnol Bioeng (2007) 1.04
Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg (2005) 1.03
Declining expression of a single epithelial cell-autonomous gene accelerates age-related thymic involution. Aging Cell (2010) 1.03
High-throughput gene discovery in the rat. Genome Res (2004) 1.02
Diagnostic radiation exposure in pediatric trauma patients. J Trauma (2011) 1.02
Guidelines and considerations for conducting experiments using tissue microarrays. Histopathology (2013) 1.02
3D-printed devices for continuous-flow organic chemistry. Beilstein J Org Chem (2013) 1.01
Continuous parallel ESI-MS analysis of reactions carried out in a bespoke 3D printed device. Beilstein J Nanotechnol (2013) 1.00
Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours. Int J Cancer (2006) 1.00
Spontaneous assembly and real-time growth of micrometre-scale tubular structures from polyoxometalate-based inorganic solids. Nat Chem (2009) 1.00
On the histone lysine methyltransferase activity of fungal metabolite chaetocin. J Med Chem (2013) 0.99
Dyspnea during daily activities in chronic spinal cord injury. Arch Phys Med Rehabil (2005) 0.99
Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale. J R Soc Interface (2010) 0.99
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Hum Genet (2013) 0.99
Safety of large-volume thoracentesis. Conn Med (2010) 0.98
On the determination of the stereochemistry of semisynthetic natural product analogues using chiroptical spectroscopy: desulfurization of epidithiodioxopiperazine fungal metabolites. Chemistry (2011) 0.98
Interference risk and the function of dynamic shifts in calling in the gray treefrog (Hyla versicolor). J Comp Psychol (2008) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study. Ann Intern Med (2016) 0.97
Unprecedented bilayer topologies in 5- and 6-connected framework polymers. Chem Commun (Camb) (2004) 0.96
Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci (2003) 0.94
General one-pot, three-step methodology leading to an extended class of N-heterocyclic cations: spontaneous nucleophilic addition, cyclization, and hydride loss. J Org Chem (2004) 0.94
Dual repair modulation reverses Temozolomide resistance in vitro. Mol Cancer Ther (2004) 0.94